ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs

Rhea-AI Summary

ImmunoGen Inc. (NASDAQ: IMGN) has appointed Mimi Huizinga, MD, MPH, FACP as Senior Vice President and Head of Medical Affairs. This new role emphasizes the growing importance of Medical Affairs alongside R&D and Commercial operations, particularly as the company prepares to launch its lead candidate, mirvetuximab soravtansine, for ovarian cancer. Dr. Huizinga joins from Rafael Holdings, bringing extensive experience in oncology and medical affairs, previously holding significant roles at Novartis and Premier, Inc.

Positive

• Appointment of Mimi Huizinga as Senior VP and Head of Medical Affairs expected to strengthen the leadership team.
• Her extensive experience in oncology may enhance the company's capacity to advance their ADC portfolio and improve stakeholder engagement.

Negative

• Concerns about continuity and potential experience gaps in senior leadership.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga, MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.

“As evidence generation and stakeholder engagement play increasingly important roles in delivering innovative therapies to patients, Medical Affairs has evolved to a third strategic pillar of our business, alongside R&D and Commercial,” said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. “With her clinical experience, medical and data analytics expertise, and strong relationships with key stakeholders in the field of oncology, I am pleased to welcome Mimi to ImmunoGen’s executive team to lead our growing Medical Affairs organization. In this newly-created position, she will play a critical role as we work to bring our lead candidate, mirvetuximab soravtansine, to women living with ovarian cancer in the second half of this year and advance the rest of our portfolio of novel ADCs.”

Dr. Huizinga joins ImmunoGen from Rafael Holdings where she served as Chief Medical Officer and Head of Research and Development and was responsible for leading the Company’s discovery and development programs. Prior to joining Rafael, she served as SVP, Head of US Oncology Medical for Novartis, overseeing the clinical development and medical affairs activities of the Novartis oncology portfolio in the US. Before leading the medical function, Dr. Huizinga built and led the strategic data and digital function for the US Oncology business unit at Novartis. During her time at Novartis, she participated in more than a dozen product and indication launches. Prior to Novartis, Dr. Huizinga was the Chief Health Information Officer at Premier, Inc., where she led quality and population health strategies and the Applied Sciences division that formed partnerships with a number of pharmaceutical companies around evidence generation needs. Earlier in her career, Dr. Huizinga served as the VP of Quality at Lifepoint Health, was an associate at McKinsey & Company, and an Assistant Professor at Johns Hopkins University School of Medicine. She serves as an independent director at HealthMyne, a radiomics company. Dr. Huizinga holds an MD and MPH from Vanderbilt University and is a fellow of the American College of Physicians.

“I am excited to join ImmunoGen at such an important time, and to lead a growing global Medical Affairs function that supports the launch of our pivotal programs and the development of our earlier stage assets,” said Dr. Huizinga. “Healthcare innovation is my passion and I look forward to building a team focused on delivering high-quality data, education, and outcomes for patients, caregivers, healthcare professionals, and payors.”

ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the occurrence, timing, and outcome of regulatory events related to the Company's product candidates, in particular with respect to mirvetuximab soravtansine, and the launch of mirvetuximab soravtansine in the second half of 2022; and the Company’s business and product development of novel ADCs. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes, including approval of the Company’s biologics license application for mirvetuximab soravtansine; the Company's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, and other reports filed with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220131005121/en/

INVESTOR RELATIONS AND MEDIA CONTACTS

ImmunoGen

Courtney O'Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com

Source: ImmunoGen Inc.

FAQ

Who is the newly appointed head of Medical Affairs at ImmunoGen?

Mimi Huizinga, MD, MPH, FACP, has been appointed as Senior Vice President and Head of Medical Affairs at ImmunoGen.

What is the significance of the new role of Medical Affairs in ImmunoGen?

The role supports stakeholder engagement and evidence generation as strategic pillars alongside R&D and Commercial, critical for advancing their product candidates.

What is the background of Mimi Huizinga?

Mimi Huizinga previously served as Chief Medical Officer at Rafael Holdings and held senior positions at Novartis, developing and launching oncology products.

What impact might Mimi Huizinga's appointment have on ImmunoGen's drug candidates?

Her appointment is expected to positively influence the advancement of the lead candidate, mirvetuximab soravtansine, and other ADCs in the pipeline.

When is the expected launch of mirvetuximab soravtansine?

The launch of mirvetuximab soravtansine is anticipated in the second half of 2022.